1514 related articles for article (PubMed ID: 33936746)
41. Complete Genome Sequence of a SARS-CoV-2 Strain Sampled in Morocco in May 2020, Obtained Using Sanger Sequencing.
Rfaki A; Touil N; Hemlali M; Alaoui Amine S; Melloul M; El Alaoui MA; Elannaz H; Lahlou AI; Elouennass M; Ennibi K; El Fahime E
Microbiol Resour Announc; 2021 May; 10(20):. PubMed ID: 34016683
[TBL] [Abstract][Full Text] [Related]
42. Coding-Complete Genome Sequences of 11 SARS-CoV-2 B.1.1.7 and B.1.351 Variants from Metro Manila, Philippines.
Velasco JM; Chinnawirotpisan P; Valderama MT; Joonlasak K; Manasatienkij W; Huang A; Diones PC; Navarro FC; Vila V; Tabinas H; Chua D; Fernandez S; Jones A; Klungthong C
Microbiol Resour Announc; 2021 Jul; 10(28):e0049821. PubMed ID: 34264104
[TBL] [Abstract][Full Text] [Related]
43. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant.
Deng X; Garcia-Knight MA; Khalid MM; Servellita V; Wang C; Morris MK; Sotomayor-González A; Glasner DR; Reyes KR; Gliwa AS; Reddy NP; Sanchez San Martin C; Federman S; Cheng J; Balcerek J; Taylor J; Streithorst JA; Miller S; Sreekumar B; Chen PY; Schulze-Gahmen U; Taha TY; Hayashi JM; Simoneau CR; Kumar GR; McMahon S; Lidsky PV; Xiao Y; Hemarajata P; Green NM; Espinosa A; Kath C; Haw M; Bell J; Hacker JK; Hanson C; Wadford DA; Anaya C; Ferguson D; Frankino PA; Shivram H; Lareau LF; Wyman SK; Ott M; Andino R; Chiu CY
Cell; 2021 Jun; 184(13):3426-3437.e8. PubMed ID: 33991487
[TBL] [Abstract][Full Text] [Related]
44. Characterization of an attenuated SARS-CoV-2 variant with a deletion at the S1/S2 junction of the spike protein.
Wang P; Lau SY; Deng S; Chen P; Mok BW; Zhang AJ; Lee AC; Chan KH; Tam RC; Xu H; Zhou R; Song W; Liu L; To KK; Chan JF; Chen Z; Yuen KY; Chen H
Nat Commun; 2021 May; 12(1):2790. PubMed ID: 33986286
[TBL] [Abstract][Full Text] [Related]
45. Structural basis for broad coronavirus neutralization.
Sauer MM; Tortorici MA; Park YJ; Walls AC; Homad L; Acton OJ; Bowen JE; Wang C; Xiong X; de van der Schueren W; Quispe J; Hoffstrom BG; Bosch BJ; McGuire AT; Veesler D
Nat Struct Mol Biol; 2021 Jun; 28(6):478-486. PubMed ID: 33981021
[TBL] [Abstract][Full Text] [Related]
46. A novel diagnostic test to screen SARS-CoV-2 variants containing E484K and N501Y mutations.
Zhao Y; Lee A; Composto K; Cunningham MH; Mediavilla JR; Fennessey S; Corvelo A; Chow KF; Zody M; Chen L; Kreiswirth BN; Perlin DS
Emerg Microbes Infect; 2021 Dec; 10(1):994-997. PubMed ID: 33977858
[TBL] [Abstract][Full Text] [Related]
47. A SARS-CoV-2 Variant with L452R and E484Q Neutralization Resistance Mutations.
Verghese M; Jiang B; Iwai N; Mar M; Sahoo MK; Yamamoto F; Mfuh KO; Miller J; Wang H; Zehnder J; Pinsky BA
J Clin Microbiol; 2021 Jun; 59(7):e0074121. PubMed ID: 33952596
[No Abstract] [Full Text] [Related]
48. Emergence and Spread of SARS-CoV-2 Lineages B.1.1.7 and P.1 in Italy.
Di Giallonardo F; Puglia I; Curini V; Cammà C; Mangone I; Calistri P; Cobbin JCA; Holmes EC; Lorusso A
Viruses; 2021 Apr; 13(5):. PubMed ID: 33946747
[TBL] [Abstract][Full Text] [Related]
49. D936Y and Other Mutations in the Fusion Core of the SARS-CoV-2 Spike Protein Heptad Repeat 1: Frequency, Geographical Distribution, and Structural Effect.
Oliva R; Shaikh AR; Petta A; Vangone A; Cavallo L
Molecules; 2021 Apr; 26(9):. PubMed ID: 33946306
[TBL] [Abstract][Full Text] [Related]
50. Mutational heterogeneity in spike glycoproteins of severe acute respiratory syndrome coronavirus 2.
Mathur A; Raj S; Jha NK; Jha SK; Rathi B; Kumar D
3 Biotech; 2021 May; 11(5):236. PubMed ID: 33936927
[TBL] [Abstract][Full Text] [Related]
51. Novel SARS-CoV-2 variants: the pandemics within the pandemic.
Boehm E; Kronig I; Neher RA; Eckerle I; Vetter P; Kaiser L;
Clin Microbiol Infect; 2021 Aug; 27(8):1109-1117. PubMed ID: 34015535
[TBL] [Abstract][Full Text] [Related]
52. An NTD supersite of attack.
Lok SM
Cell Host Microbe; 2021 May; 29(5):744-746. PubMed ID: 33984277
[TBL] [Abstract][Full Text] [Related]
53. Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study.
Hatzl S; Posch F; Sareban N; Stradner M; Rosskopf K; Reisinger AC; Eller P; Schörghuber M; Toller W; Sloup Z; Prüller F; Gütl K; Pilz S; Rosenkranz AR; Greinix HT; Krause R; Schlenke P; Schilcher G
Ann Intensive Care; 2021 May; 11(1):73. PubMed ID: 33978844
[TBL] [Abstract][Full Text] [Related]
54. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes.
Guo Y; Huang L; Zhang G; Yao Y; Zhou H; Shen S; Shen B; Li B; Li X; Zhang Q; Chen M; Chen D; Wu J; Fu D; Zeng X; Feng M; Pi C; Wang Y; Zhou X; Lu M; Li Y; Fang Y; Lu YY; Hu X; Wang S; Zhang W; Gao G; Adrian F; Wang Q; Yu F; Peng Y; Gabibov AG; Min J; Wang Y; Huang H; Stepanov A; Zhang W; Cai Y; Liu J; Yuan Z; Zhang C; Lou Z; Deng F; Zhang H; Shan C; Schweizer L; Sun K; Rao Z
Nat Commun; 2021 May; 12(1):2623. PubMed ID: 33976198
[TBL] [Abstract][Full Text] [Related]
55. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival.
Dispinseri S; Secchi M; Pirillo MF; Tolazzi M; Borghi M; Brigatti C; De Angelis ML; Baratella M; Bazzigaluppi E; Venturi G; Sironi F; Canitano A; Marzinotto I; Tresoldi C; Ciceri F; Piemonti L; Negri D; Cara A; Lampasona V; Scarlatti G
Nat Commun; 2021 May; 12(1):2670. PubMed ID: 33976165
[TBL] [Abstract][Full Text] [Related]
56. SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes.
Jungreis I; Sealfon R; Kellis M
Nat Commun; 2021 May; 12(1):2642. PubMed ID: 33976134
[TBL] [Abstract][Full Text] [Related]
57. The SARS-CoV-2 Transcriptome and the Dynamics of the S Gene Furin Cleavage Site in Primary Human Airway Epithelia.
Zou W; Xiong M; Hao S; Zhang EY; Baumlin N; Kim MD; Salathe M; Yan Z; Qiu J
mBio; 2021 May; 12(3):. PubMed ID: 33975939
[TBL] [Abstract][Full Text] [Related]
58. Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2.
Rajasekharan S; Milan Bonotto R; Nascimento Alves L; Kazungu Y; Poggianella M; Martinez-Orellana P; Skoko N; Polez S; Marcello A
Viruses; 2021 Apr; 13(5):. PubMed ID: 33946304
[TBL] [Abstract][Full Text] [Related]
59. Relationship of SARS-CoV-2-specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection.
Riou C; du Bruyn E; Stek C; Daroowala R; Goliath RT; Abrahams F; Said-Hartley Q; Allwood BW; Hsiao NY; Wilkinson KA; Arlehamn CSL; Sette A; Wasserman S; Wilkinson RJ;
J Clin Invest; 2021 Jun; 131(12):. PubMed ID: 33945513
[TBL] [Abstract][Full Text] [Related]
60. Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia.
Camou F; Tinevez C; Beguet-Yachine M; Bellecave P; Ratiarison D; Tumiotto C; Lafarge X; Guisset O; Mourissoux G; Lafon ME; Bonnet F; Issa N
J Med Virol; 2021 Sep; 93(9):5594-5598. PubMed ID: 33942327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
